| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
In 2010, Yogen Dalal, after being diagnosed, co-founded Glooko with the mission to make diabetes management easier by liberating data from diabetes devices to help patients and providers to make smarter decisions.
Density measures how people use space in real-time without invading privacy. Using proprietary depth sensors and deep learning algorithms, the platform accurately and anonymously counts people in real time.
BotDoc is the secure FedEx of Data. We pick data up and deliver it securely. A disruptive technology in the data-transport space! Relax.. just BotDoc-it